ENTADFI (finasteride/tadalafil)
BENIGN PROSTATIC HYPERPLASIA
VERU INC.
Indication
Benign prostatic hyperplasia
Benign prostatic hyperplasia is a nonmalignant urological disorder characterized by the progressive proliferation of stromal and epithelial cells within the transition zone of the prostate gland. Read more about Benign prostatic hyperplasia
3 drugs 3 manufacturers
Drugs that treat it
Common Benign prostatic hyperplasia therapies.
ENTADFI (finasteride/tadalafil)
BENIGN PROSTATIC HYPERPLASIA
VERU/BLUE WATER
ENTADFI (finasteride/tadalafil)
5 ALPHA-REDUCTASE INHIBITORS·BENIGN PROSTATIC HYPERPLASIA
BLUE WATER BIOT
Filter & compare in the drug finder →Opens the drug finder with Benign prostatic hyperplasia preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonBenign prostatic hyperplasia is a nonmalignant urological disorder characterized by the progressive proliferation of stromal and epithelial cells within the transition zone of the prostate gland.
It predominantly affects aging men, with its histological and clinical prevalence increasing markedly after the fourth decade of life.
As the expanding tissue compresses the prostatic urethra, it induces bladder outlet obstruction that frequently manifests as lower urinary tract symptoms, including urinary frequency, urgency, nocturia, weak stream, hesitancy, and incomplete bladder emptying.
Untreated or progressive obstruction may lead to secondary complications such as acute urinary retention, recurrent urinary tract infections, bladder calculi, and hydronephrosis.
- nih.gov
Benign prostatic hyperplasia is a nonmalignant urological disorder characterized by the progressive proliferation of stromal and epithelial cells within the transition zone of the prostate gland As the expanding tissue compresses the prostatic urethra, it induces bladder outlet obstruction that frequently manifests as lower urinary tract symptoms, including urinary frequency, urgency, nocturia, weak stream, hesitancy, and incomplete bladder emptying Untreated or progressive obstruction may lead ...
- nih.gov
Benign prostatic hyperplasia is a nonmalignant urological disorder characterized by the progressive proliferation of stromal and epithelial cells within the transition zone of the prostate gland As the expanding tissue compresses the prostatic urethra, it induces bladder outlet obstruction that frequently manifests as lower urinary tract symptoms, including urinary frequency, urgency, nocturia, weak stream, hesitancy, and incomplete bladder emptying
- nih.gov
It predominantly affects aging men, with its histological and clinical prevalence increasing markedly after the fourth decade of life
- nih.gov
It predominantly affects aging men, with its histological and clinical prevalence increasing markedly after the fourth decade of life
- wikipedia.org
Untreated or progressive obstruction may lead to secondary complications such as acute urinary retention, recurrent urinary tract infections, bladder calculi, and hydronephrosis
Personalize your experience
Follow Benign prostatic hyperplasia and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.